menu
    • menu
    [{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"TR009","moa":"Dll4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Trigr \/ Elpiscience Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Elpiscience Biopharmaceuticals"},{"orgOrder":0,"company":"Trigr","sponsor":"Compass Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"CTX-009","moa":"Dll4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Trigr \/ Compass Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Compass Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Trigr

    Menu

    Trigr

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trigr

                            Europe arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Trigr

                            Europe arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTX-009

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Compass Therapeutics

                            Deal Size : $14.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.

                            Details : Compass Therapeutics obtains global rights to TR009, a novel bispecific antibody and inhibitor of the notch pathway targeting DLL4 and VEGF-A.

                            Brand Name : TR009

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 13, 2021

                            Lead Product(s) : CTX-009

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Compass Therapeutics

                            Deal Size : $14.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trigr

                            Europe arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Trigr

                            Europe arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asciminib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Elpiscience

                            Deal Size : $117.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transact...

                            Details : Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territor...

                            Brand Name : ABL001

                            Molecule Type : Large molecule

                            Upfront Cash : $7.0 million

                            January 20, 2021

                            Lead Product(s) : Asciminib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Elpiscience

                            Deal Size : $117.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth